PCSK9 antibody
Contáctenos para saber el precio
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
PCSK9 antibody
category
Primary Antibodies
provider
FineTest
reference
FNab06227
tested applications
ELISA, WB, IHC, IF
Description
This gene encodes a member of the subtilisin-like proprotein convertase family, which includes proteases that process protein and peptide precursors trafficking through regulated or constitutive branches of the secretory pathway. The encoded protein undergoes an autocatalytic processing event with its prosegment in the ER and is constitutively secreted as an inactive protease into the extracellular matrix and trans-Golgi network. It is expressed in liver, intestine and kidney tissues and escorts specific receptors for lysosomal degradation. It plays a role in cholesterol and fatty acid metabolism. Mutations in this gene have been associated with autosomal dominant familial hypercholesterolemia. Alternative splicing results in multiple transcript variants.
Documents del producto
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | proprotein convertase subtilisin/kexin type 9 (PCSK9) |
| Host | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Recommended Dilution | WB: 1:500 - 1:2000; IHC: 1:50 - 1:200; IF: 1:50 - 1:100 |
| Clonality | polyclonal |
| Conjugation | Unconjugated |
| Isotype | IgG |
| Observed MW | 72 kDa |
| Purity | ≥95% as determined by SDS-PAGE |
| Purification | Immunogen affinity purified |
| Size 1 | 100µg |
| Form | liquid |
| Tested Applications | ELISA, WB, IHC, IF |
| Storage | PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20℃ for 12 months (Avoid repeated freeze / thaw cycles.) |
| UniProt ID | Q8NBP7 |
| Gene ID | 255738 |
| Alias | FH3,PC9,FHCL3,NARC1,LDLCQ1,NARC-1,HCHOLA3 |
| Background | Antibody anti-PCSK9 |
| Status | RUO |
| Note | Mol. Weight 72 kDa |
Descripción
PCSK9 is a serine protease that plays a central role in cholesterol metabolism by regulating the levels of low-density lipoprotein receptors (LDLR) on the cell surface. PCSK9 binds to LDL receptors, promoting their internalization and subsequent degradation in lysosomes, which reduces the uptake of LDL cholesterol (LDL-C) from the bloodstream. Elevated PCSK9 activity leads to hypercholesterolemia and increases the risk of cardiovascular disease due to excessive circulating LDL-C levels. In contrast, loss-of-function mutations in PCSK9 result in reduced LDL receptor degradation, leading to low plasma cholesterol levels and decreased cardiovascular risk. PCSK9 inhibitors, such as monoclonal antibodies (e.g., alirocumab and evolocumab), are highly effective therapies for hypercholesterolemia and cardiovascular disease, as they block PCSK9's activity, preserving LDL receptors on cell surfaces to enhance cholesterol clearance. Beyond lipid metabolism, PCSK9 has been implicated in inflammation, immune regulation, and other pathological processes, making it a versatile target for therapeutic intervention. Its crucial role in cholesterol homeostasis underscores its significance in cardiovascular health and disease management.
Related Products
Guinea pig PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) ELISA Kit
Ver Producto
Human PCSK9 (Proprotein convertase subtilisin/kexin type 9) ELISA Kit
Ver Producto